Every drug candidate depends on hundreds of analytical decisions, batch release, stability, method validation, clinical sample review. Those decisions are still made manually, one by one, by scientists who spend most of their time reviewing routine data instead of solving hard problems. As AI accelerates discovery pipelines, the gap between how fast molecules are generated and how fast labs can validate them is widening.
Expert Intelligence (EI) builds AI that automates those decisions. Its intelligence platform reads raw instrument data, applies the judgment a scientist would, and delivers a governed, audit-ready result, so scientists review exceptions.
The reason this problem has persisted despite the AI boom: standard AI requires large training datasets that regulated labs don't have and can't expose. Expert Intelligence's proprietary Limited Sample Model (LSM) learns from as few as 30–50 expert-reviewed examples and operates directly on raw instrument signals, making it deployable where other AI can't go.
"Self-driving labs do not start with robots. They start with trusted analytical decisions," said Lalin Theverapperuma, PhD, Founder and CEO of Expert Intelligence. "We built our platform for environments where a wrong decision has real consequences, and every output must stand up to regulatory review. Based on internal testing across selected regulated laboratory environments, Expert Intelligence delivered up to 50 times faster analytical review, up to 7 times greater accuracy, and up to 10 times faster time-to-value.
Launching at BIO 2026: Expert Intelligence Signal
The company's core product, EI Flow, automates analytical review workflow by workflow across small molecule, biologics characterization, and advanced therapeutic methods from LC-MS and HPLC to icIEF, Glycan, Intact Mass, ADC, and Proteomics. At BIO 2026, Expert Intelligence is launching Expert Intelligence Signal (EI Signal), the cross-pipeline fabric built on top of EI Flow. EI Signal unifies expert-grade analytical decisions across every instrument, method, site, and stage of development from Discovery through DMPK, CMC, and QC into a single live source of truth. Because it continuously learns from real-time data, it detects emerging issues before they become deviations, batch failures, or regulatory findings. EI Signal is already in production at one of the world's largest pharmaceutical companies.
Expert Intelligence was founded by Lalin Theverapperuma, PhD, who spent two decades building precision ML at Apple, Meta, Intel, and Bosch before applying that standard to the regulated lab. The company is backed by a $5.8 million seed round led by Sierra Ventures.
Visit Expert Intelligence in the AI Zone, Booth #3916, at the San Diego Convention Center, June 22–25, San Diego. To schedule a meeting [email protected].
Expert Intelligence automates analytical data review and decision workflows for pharmaceutical, biotechnology, CRO, CDMO, and clinical laboratory organizations. EI Flow covers small molecule, biologics, and advanced therapeutic workflows. EI Signal connects those decisions into a cross-pipeline intelligence layer with early issue detection. Backed by Sierra Ventures. More at www.expertintelligence.ai.
